Beneski Benjamin Machinas 4

What Happened

• Benjamin Machinas Beneski, SVP and Chief Technical Officer of Allogene Therapeutics (ALLO), had a small open-market sale and received two derivative awards on Feb 2, 2026. He sold 7,549 shares at a weighted-average price of $1.73 for proceeds of $13,060 (sale reported as code S). He was also granted two awards totaling 479,477 derivative units (373,757 and 105,720) reported at $0.00 (code A).
• The sale was a sell-to-cover to satisfy tax withholding obligations tied to the vesting of restricted stock units (per footnote F1), not characterized as a discretionary market sale.

Key Details

• Transaction date: February 2, 2026. Form filed February 4, 2026 (timely).
• Sale: 7,549 shares disposed; weighted-average price $1.73; prices in the sale ranged $1.71–$1.75 (footnote F2). Proceeds reported: $13,060.
• Awards: two derivative grants totaling 479,477 units (373,757 and 105,720) reported with $0.00 price (derivative awards).
• Vesting/award notes: one award follows a 4-year annual vesting schedule (RSUs—4 equal annual installments from Feb 2, 2026; footnote F4). The other award includes an option-style vesting schedule with 25% vesting on Feb 2, 2027 and the remainder vesting in 36 equal monthly installments thereafter (footnote F3).
• Shares owned after the transactions: not specified in the provided excerpt.
• Footnotes: F1 = sale was mandatory "sell-to-cover" for taxes; F2 = weighted-average sale price; F3 & F4 = vesting schedules and RSU description.

Context

• The sale appears routine (sell-to-cover for tax withholding) and is commonly required by equity plans; it should not be interpreted as a discretionary bearish signal. The awards are derivative grants (one set of RSUs and one set with an option-style vesting schedule) that vest over time subject to continued service.